Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioblastoma 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Gliosarcoma 7Central Nervous System Neoplasms 7Prostatic Neoplasms 5Lymphoma 5Breast Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Kidney Neoplasms 4Pancreatic Neoplasms 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Head and Neck Neoplasms 3Brain Neoplasms 3Urogenital Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Multiple Myeloma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Large Cell 2Adenocarcinoma of Lung 2

Interventions

Cisplatin 55Carboplatin 50pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11130-nm albumin-bound paclitaxel 11Sunitinib 10Platinum 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × motexafin gadolinium × Clear all
NCT00365183 2013-10-31

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Pharmacyclics LLC.

Phase 2 Terminated
74 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡